SAFETY DATA SHEET
Grazoprevir / Elbasvir Formulation

Section 1: Identification

Product name: Grazoprevir / Elbasvir Formulation

Manufacturer or supplier’s details
Company: MSD
Address: 33 Whakatiki Street - Private Bag 908
Upper Hutt - New Zealand
Telephone: +1-908-740-4000
Emergency telephone number: +1-908-423-6000
E-mail address: EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use
Recommended use: Pharmaceutical

Section 2: Hazard identification

GHS Classification
Not a hazardous substance or mixture.

GHS label elements
Not a hazardous substance or mixture.

Other hazards which do not result in classification
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

Section 3: Composition/information on ingredients

Substance / Mixture: Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>&lt; 10</td>
</tr>
<tr>
<td>Grazoprevir</td>
<td>1350462-55-3</td>
<td>&lt; 10</td>
</tr>
<tr>
<td>Elbasvir</td>
<td>1370468-36-2</td>
<td>&lt; 10</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>&lt; 10</td>
</tr>
<tr>
<td>Titanium dioxide</td>
<td>13463-67-7</td>
<td>&lt; 1</td>
</tr>
</tbody>
</table>

Section 4: First-aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
If inhaled: If inhaled, remove to fresh air. Get medical attention.
In case of skin contact: Wash with water and soap. Get medical attention if symptoms occur.
In case of eye contact: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed: Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.
Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician: Treat symptomatically and supportively.

Section 5: Fire-fighting measures

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical
Unsuitable extinguishing media: None known.
Specific hazards during firefighting: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products: Carbon oxides
Metal oxides
Chlorine compounds
Nitrogen oxides (NOx)
Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.
Hazchem Code: 2Z

Section 6: Accidental release measures

Personal precautions, protective equipment and emergency procedures: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up:
- Sweep up or vacuum up spillage and collect in suitable container for disposal.
- Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
- Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
- Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
- Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Section 7: Handling and storage

Technical measures:
- Static electricity may accumulate and ignite suspended dust causing an explosion.
- Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation:
- Use only with adequate ventilation.

Advice on safe handling:
- Do not breathe dust.
- Do not swallow.
- Avoid contact with eyes.
- Avoid prolonged or repeated contact with skin.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Minimize dust generation and accumulation.
- Keep container closed when not in use.
- Keep away from heat and sources of ignition.
- Take precautionary measures against static discharges.
- Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures:
- If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
- When using do not eat, drink or smoke.
- Wash contaminated clothing before re-use.
- The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage:
- Keep in properly labelled containers.
- Store in accordance with the particular national regulations.

Materials to avoid:
- Do not store with the following product types:
  - Strong oxidizing agents
### Section 8: Exposure controls/personal protection

#### Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>WES-TWA</td>
<td>10 mg/m³</td>
<td>NZ OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td>Grazoprevir</td>
<td>1350462-55-3</td>
<td>TWA</td>
<td>85 µg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>850 µg/100 cm²</td>
<td>Internal</td>
</tr>
<tr>
<td>Elbasvir</td>
<td>1370468-36-2</td>
<td>TWA</td>
<td>100 µg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>WES-TWA</td>
<td>10 mg/m³</td>
<td>NZ OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Inhalable particulate matter)</td>
<td>3 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td>Titanium dioxide</td>
<td>13463-67-7</td>
<td>WES-TWA</td>
<td>10 mg/m³</td>
<td>NZ OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA</td>
<td>10 mg/m³ (Titanium dioxide)</td>
<td>ACGIH</td>
</tr>
</tbody>
</table>

#### Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

#### Personal protective equipment

**Respiratory protection**

If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

**Filter type**

Particulates type

**Hand protection**

Chemical-resistant gloves

**Remarks**

Consider double gloving.

**Eye protection**

Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection**

Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis-
Section 9: Physical and chemical properties

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance</td>
<td>powder</td>
</tr>
<tr>
<td>Colour</td>
<td>white</td>
</tr>
<tr>
<td>Odour</td>
<td>No data available</td>
</tr>
<tr>
<td>Odour Threshold</td>
<td>No data available</td>
</tr>
<tr>
<td>pH</td>
<td>No data available</td>
</tr>
<tr>
<td>Melting point/freezing point</td>
<td>No data available</td>
</tr>
<tr>
<td>Initial boiling point and boiling range</td>
<td>No data available</td>
</tr>
<tr>
<td>Flash point</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Evaporation rate</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Flammability (solid, gas)</td>
<td>May form explosive dust-air mixture during processing, handling or other means.</td>
</tr>
<tr>
<td>Flammability (liquids)</td>
<td>No data available</td>
</tr>
<tr>
<td>Upper explosion limit / Upper flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Lower explosion limit / Lower flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapour pressure</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Relative vapour density</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Relative density</td>
<td>No data available</td>
</tr>
<tr>
<td>Density</td>
<td>No data available</td>
</tr>
<tr>
<td>Solubility(ies)</td>
<td>Water solubility</td>
</tr>
<tr>
<td>Partition coefficient: n-octanol/water</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Auto-ignition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Decomposition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity</td>
<td>Viscosity, kinematic</td>
</tr>
<tr>
<td>Viscosity</td>
<td>Not applicable</td>
</tr>
</tbody>
</table>
Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Particle size : No data available

Section 10: Stability and reactivity

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

Section 11: Toxicological information

Exposure routes : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Components:

Cellulose:
Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Grazoprevir:
Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Elbasvir:
Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
LD50 (Mouse): > 1,000 mg/kg

Magnesium stearate:
Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 423
Assessment: The substance or mixture has no acute oral toxicity
Remarks: Based on data from similar materials

Acute dermal toxicity: LD50 (Rabbit): > 2,000 mg/kg
Remarks: Based on data from similar materials

Titanium dioxide:
Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity: LC50 (Rat): > 6.82 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Assessment: The substance or mixture has no acute inhalation toxicity

Skin corrosion/irritation
Not classified based on available information.

Components:

Grazoprevir:
Result: No skin irritation

Elbasvir:
Species: reconstructed human epidermis (RhE)
Result: No skin irritation

Magnesium stearate:
Species: Rabbit
Result: No skin irritation
Remarks: Based on data from similar materials

Titanium dioxide:
Species: Rabbit
Result: No skin irritation

Serious eye damage/eye irritation
Not classified based on available information.

Components:

Grazoprevir:
Species: Bovine cornea
Result: No eye irritation

Elbasvir:
Species: Bovine cornea
Result: No eye irritation
Magnesium stearate:
Species: Rabbit
Result: No eye irritation
Remarks: Based on data from similar materials

Titanium dioxide:
Species: Rabbit
Result: No eye irritation

Respiratory or skin sensitisation
Skin sensitisation
Not classified based on available information.
Respiratory sensitisation
Not classified based on available information.

Components:

Grazoprevir:
Test Type: Local lymph node assay (LLNA)
Exposure routes: Dermal
Result: Not a skin sensitizer.

Elbasvir:
Test Type: Local lymph node assay (LLNA)
Exposure routes: Dermal
Species: Mouse
Result: negative

Magnesium stearate:
Test Type: Maximisation Test
Exposure routes: Skin contact
Species: Guinea pig
Method: OECD Test Guideline 406
Result: negative
Remarks: Based on data from similar materials

Titanium dioxide:
Test Type: Local lymph node assay (LLNA)
Exposure routes: Skin contact
Species: Mouse
Result: negative

Chronic toxicity
Germ cell mutagenicity
Not classified based on available information.

Components:

Cellulose:
SAFETY DATA SHEET
Grazoprevir / Elbasvir Formulation

Genotoxicity in vitro:
- **Test Type:** Bacterial reverse mutation assay (AMES)
  - Result: negative

Genotoxicity in vivo:
- **Test Type:** Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  - Species: Mouse
  - Application Route: Ingestion
  - Result: negative

Grazoprevir:
- Genotoxicity in vitro:
  - **Test Type:** Bacterial reverse mutation assay (AMES)
    - Result: negative
  - **Test Type:** Chromosome aberration test in vitro
    - Result: negative

- Genotoxicity in vivo:
  - **Test Type:** In vivo micronucleus test
    - Application Route: Oral
    - Result: negative

- Germ cell mutagenicity - Assessment:
  - Weight of evidence does not support classification as a germ cell mutagen.

Elbasvir:
- Genotoxicity in vitro:
  - **Test Type:** Bacterial reverse mutation assay (AMES)
    - Result: negative
  - **Test Type:** Chromosome aberration test in vitro
    - Result: negative

- Genotoxicity in vivo:
  - **Test Type:** In vivo micronucleus test
    - Species: Rat
    - Application Route: Oral
    - Result: negative

- Germ cell mutagenicity - Assessment:
  - Weight of evidence does not support classification as a germ cell mutagen.

Magnesium stearate:
- Genotoxicity in vitro:
  - **Test Type:** In vitro mammalian cell gene mutation test
    - Result: negative
    - Remarks: Based on data from similar materials
  - **Test Type:** Chromosome aberration test in vitro
    - Method: OECD Test Guideline 473
    - Result: negative
    - Remarks: Based on data from similar materials
  - **Test Type:** Bacterial reverse mutation assay (AMES)
    - Result: negative
Titanium dioxide:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Genotoxicity in vivo: Test Type: In vivo micronucleus test
Species: Mouse
Result: negative

Carcinogenicity
Not classified based on available information.

Components:
Cellulose:
Species: Rat
Application Route: Ingestion
Exposure time: 72 weeks
Result: negative

Titanium dioxide:
Species: Rat
Application Route: Inhalation (dust/mist/fume)
Exposure time: 2 Years
Method: OECD Test Guideline 453
Result: positive
Remarks: The mechanism or mode of action may not be relevant in humans.

Carcinogenicity - Assessment: Limited evidence of carcinogenicity in inhalation studies with animals.

Reproductive toxicity
Not classified based on available information.

Components:
Cellulose:
Effects on fertility: Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on foetal development: Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Result: negative

Grazoprevir:
Effects on fertility: Test Type: Fertility
Species: Rat
Application Route: Oral
Fertility: NOAEL: 400 mg/kg body weight
Result: negative

Test Type: Multi-generation study
Species: Rat
Application Route: Oral
Fertility: NOAEL: 400 mg/kg body weight
Result: No effects on fertility, No effects on foetal development

Elbasvir:
Effects on fertility
: Test Type: Fertility/early embryonic development
Species: Rat, male and female
Application Route: Oral
Fertility: NOAEL: 1,000 mg/kg body weight
Result: No effects on fertility

Effects on foetal development
: Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Embryo-foetal toxicity: NOAEL: 200 mg/kg body weight
Result: No effects on foetal development

Species: Rabbit
Application Route: Oral
Embryo-foetal toxicity: NOAEL: 200 mg/kg body weight
Result: No effects on foetal development

Species: Rabbit
Application Route: Intravenous
Embryo-foetal toxicity: NOAEL: 100 mg/kg body weight
Result: No effects on foetal development

Magnesium stearate:
Effects on fertility
: Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 422
Result: negative

Developmental Toxicity: NOAEL: 1,000 mg/kg body weight
Result: No effects on early embryonic development

Developmental Toxicity: NOAEL: 1,000 mg/kg body weight
Result: No effects on early embryonic development
Remarks: Based on data from similar materials

Effects on foetal development:
- Test Type: Embryo-foetal development
- Species: Rat
- Application Route: Ingestion
- Result: negative
- Remarks: Based on data from similar materials

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
Not classified based on available information.

Components:

Grazoprevir:
- Target Organs: Liver, Testis
- Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Cellulose:
- Species: Rat
- NOAEL: >= 9,000 mg/kg
- Application Route: Ingestion
- Exposure time: 90 Days

Grazoprevir:
- Species: Rat
- NOAEL: 400 mg/kg
- Application Route: Oral
- Exposure time: 30 Days
- Remarks: No significant adverse effects were reported

- Species: Rat
- NOAEL: 400 mg/kg
- Application Route: Oral
- Exposure time: 180 Days
- Remarks: No significant adverse effects were reported

- Species: Dog
- NOAEL: 15 mg/kg
- LOAEL: 100 mg/kg
- Application Route: Oral
- Exposure time: 270 Days
- Target Organs: Liver, Blood, Bone marrow, gallbladder, spleen, Testis

- Species: Mouse
- NOAEL: 200 mg/kg
- LOAEL: 500 mg/kg
## SAFETY DATA SHEET

### Grazoprevir / Elbasvir Formulation

<table>
<thead>
<tr>
<th>Application Route</th>
<th>Oral</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exposure time</td>
<td>90 Days</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Liver, Kidney, Blood</td>
</tr>
</tbody>
</table>

###Species, NOAEL, LOAEL

<table>
<thead>
<tr>
<th>Species</th>
<th>Dog</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>20 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>600 mg/kg</td>
</tr>
</tbody>
</table>

###Application Route, Exposure time, Target Organs

<table>
<thead>
<tr>
<th>Application Route</th>
<th>Oral</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exposure time</td>
<td>30 Days</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Blood, Testis</td>
</tr>
</tbody>
</table>

###Species, NOAEL, Exposure time, Remarks

<table>
<thead>
<tr>
<th>Species</th>
<th>Monkey</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>Exposure time</td>
<td>8 Days</td>
</tr>
<tr>
<td>Remarks</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

###Elbasvir

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>1,000 mg/kg</td>
</tr>
</tbody>
</table>

###Application Route, Exposure time, Remarks

<table>
<thead>
<tr>
<th>Application Route</th>
<th>Oral</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exposure time</td>
<td>180 d</td>
</tr>
<tr>
<td>Remarks</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

###Species, NOAEL, Application Route, Exposure time, Remarks

<table>
<thead>
<tr>
<th>Species</th>
<th>Dog</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>1,000 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>270 d</td>
</tr>
<tr>
<td>Remarks</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

###Magnesium stearate

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>&gt; 100 mg/kg</td>
</tr>
</tbody>
</table>

###Application Route, Exposure time, Remarks

<table>
<thead>
<tr>
<th>Application Route</th>
<th>Ingestion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exposure time</td>
<td>90 Days</td>
</tr>
<tr>
<td>Remarks</td>
<td>Based on data from similar materials</td>
</tr>
</tbody>
</table>

###Titanium dioxide

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>24,000 mg/kg</td>
</tr>
</tbody>
</table>

###Application Route, Exposure time

<table>
<thead>
<tr>
<th>Application Route</th>
<th>Ingestion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exposure time</td>
<td>28 Days</td>
</tr>
</tbody>
</table>

###Species, NOAEL, Application Route, Exposure time

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>10 mg/m3</td>
</tr>
<tr>
<td>Application Route</td>
<td>inhalation (dust/mist/fume)</td>
</tr>
<tr>
<td>Exposure time</td>
<td>2 yr</td>
</tr>
</tbody>
</table>

###Aspiration toxicity

Not classified based on available information.
Experience with human exposure

**Components:**

**Grazoprevir:**
- Ingestion
  - Symptoms: Headache, Gastrointestinal disturbance

**Elbasvir:**
- Ingestion
  - Symptoms: Headache, Abdominal pain, constipation, Nausea, Fatigue, muscle pain, joint pain, Dizziness, Cough, Skin irritation, rhinitis, Drowsiness, nasal congestion

### Section 12: Ecological information

**Ecotoxicity**

**Components:**

**Cellulose:**
- Toxicity to fish
  - LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
  - Exposure time: 48 h
  - Remarks: Based on data from similar materials

**Grazoprevir:**
- Toxicity to fish
  - LC50 (Cyprinodon variegatus (sheepshead minnow)): > 10 mg/l
  - Exposure time: 96 h
  - Remarks: No toxicity at the limit of solubility

  - Toxicity to daphnia and other aquatic invertebrates
    - EC50 (Daphnia magna (Water flea)): > 10 mg/l
    - Exposure time: 48 h
    - Method: OECD Test Guideline 202
    - Remarks: No toxicity at the limit of solubility
    - LC50 (Americamysis): 8.9 mg/l
    - Exposure time: 96 h

  - Toxicity to algae/aquatic plants
    - EC50 (Pseudokirchneriella subcapitata (green algae)): > 10 mg/l
    - Exposure time: 72 hrs
    - Method: OECD Test Guideline 201
    - Remarks: No toxicity at the limit of solubility
    - NOEC (Pseudokirchneriella subcapitata (green algae)): 10 mg/l
    - Exposure time: 72 hrs
    - Method: OECD Test Guideline 201
    - Remarks: No toxicity at the limit of solubility

- Toxicity to fish (Chronic toxicity)
  - NOEC (Pimephales promelas (fathead minnow)): 0.98 mg/l
  - Exposure time: 32 d
  - Method: OECD Test Guideline 210
  - Remarks: No toxicity at the limit of solubility

- Toxicity to daphnia and other aquatic invertebrates
  - NOEC (Daphnia magna (Water flea)): 5 mg/l
aquatic invertebrates (Chronic toxicity)

Toxicity to microorganisms

Exposure time: 21 d
Method: OECD Test Guideline 211

EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 1.3 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Elbasvir:

Toxicity to fish

LC50 (Lepomis macrochirus (Bluegill sunfish)): > 10 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
Remarks: No toxicity at the limit of solubility

LC50 (Menidia beryllina (Silverside)): > 10 mg/l
Exposure time: 96 h
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 10 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility

LC50 (Americamysis): 7.7 mg/l
Exposure time: 96 h
Method: US-EPA OPPTS 850.1035
Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic plants

EC50 (Pseudokirchneriella subcapitata (algae)): > 0.081 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.081 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic toxicity)

NOEC (Pimephales promelas (fathead minnow)): 0.0023 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)

NOEC (Daphnia magna (Water flea)): 0.84 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211
Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms

EC50: > 1,000 mg/l
### Magnesium stearate:

**Toxicity to fish**
- LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l
- Exposure time: 48 h
- Method: DIN 38412
- Remarks: Based on data from similar materials

**Toxicity to daphnia and other aquatic invertebrates**
- EL50 (Daphnia magna (Water flea)): > 1 mg/l
- Exposure time: 47 h
- Test substance: Water Accommodated Fraction
- Remarks: Based on data from similar materials
- No toxicity at the limit of solubility

**Toxicity to algae/aquatic plants**
- EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
- Exposure time: 72 h
- Test substance: Water Accommodated Fraction
- Method: OECD Test Guideline 201
- Remarks: Based on data from similar materials
- No toxicity at the limit of solubility

**Toxicity to microorganisms**
- EC10 (Pseudomonas putida): > 100 mg/l
- Exposure time: 16 h
- Test substance: Water Accommodated Fraction
- Remarks: Based on data from similar materials

### Titanium dioxide:

**Toxicity to fish**
- LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l
- Exposure time: 96 h
- Method: OECD Test Guideline 203

**Toxicity to daphnia and other aquatic invertebrates**
- EC50 (Daphnia magna (Water flea)): > 100 mg/l
- Exposure time: 48 h

**Toxicity to algae/aquatic plants**
- EC50 (Skeletonema costatum (marine diatom)): > 10,000 mg/l
- Exposure time: 72 h

**Toxicity to microorganisms**
- EC50: > 1,000 mg/l
Exposure time: 3 h
Method: OECD Test Guideline 209

Persistence and degradability

Components:

Cellulose:
Biodegradability: Result: Readily biodegradable.

Grazoprevir:
Biodegradability: Result: Not readily biodegradable.
Biodegradation: 66 %
Exposure time: 28 d

Elbasvir:
Biodegradability: Result: Not readily biodegradable.
Biodegradation: 37 %
Exposure time: 28 d

Magnesium stearate:
Biodegradability: Result: Not biodegradable
Remarks: Based on data from similar materials

Bioaccumulative potential

Components:

Grazoprevir:
Bioaccumulation: Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 7.62
Partition coefficient: n-octanol/water: log Pow: 3.72

Elbasvir:
Bioaccumulation: Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 82
Method: OECD Test Guideline 305
Partition coefficient: n-octanol/water: log Pow: 6.54

Magnesium stearate:
Partition coefficient: n-octanol/water: log Pow: > 4

Mobility in soil

Components:

Grazoprevir:
Distribution among environment: log Koc: 4.01
mental compartments

**Elbasvir:**
Distribution among environmental compartments: log Koc: 5.24

**Other adverse effects**
No data available

---

### Section 13: Disposal considerations

**Disposal methods**
- Waste from residues: Dispose of in accordance with local regulations.
- Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
  If not otherwise specified: Dispose of as unused product.

---

### Section 14: Transport information

**International Regulations**

**UNRTDG**
- **UN number**: UN 3077
- **Proper shipping name**: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Elbasvir)
  - **Class**: 9
  - **Packing group**: III
  - **Labels**: 9

**IATA-DGR**
- **UN/ID No.**: UN 3077
- **Proper shipping name**: Environmentally hazardous substance, solid, n.o.s. (Elbasvir)
  - **Class**: 9
  - **Packing group**: III
  - **Labels**: Miscellaneous
  - **Packing instruction (cargo aircraft)**: 956
  - **Packing instruction (passenger aircraft)**: 956
  - **Environmentally hazardous**: yes

**IMDG-Code**
- **UN number**: UN 3077
- **Proper shipping name**: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Elbasvir)
  - **Class**: 9
  - **Packing group**: III
  - **Labels**: 9
  - **EmS Code**: F-A, S-F
  - **Marine pollutant**: yes

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**
Not applicable for product as supplied.
SAFETY DATA SHEET

Grazoprevir / Elbasvir Formulation

Version 6.9
Revision Date: 27.08.2021
SDS Number: 76217-00021
Date of last issue: 08.12.2020
Date of first issue: 17.03.2015

National Regulations

NZS 5433
UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Elbasvir)
Class : 9
Packing group : III
Labels : 9
Hazchem Code : 2Z

Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

Section 15: Regulatory information

Safety, health and environmental regulations/legislation specific for the substance or mixture

HSNO Approval Number
HSR100425 Pharmaceutical Active Ingredients Group Standard 2017

HSW Controls
Certified handler certificate not required.
Tracking hazardous substance not required.
Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

The components of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined

Section 16: Other information

Further information
Date format : dd.mm.yyyy

Full text of other abbreviations
ACGIH : USA, ACGIH Threshold Limit Values (TLV)
NZ OEL : New Zealand. Workplace Exposure Standards for Atmospheric Contaminants
SAFETY DATA SHEET

Grazoprevir / Elbasvir Formulation

Version 6.9  |  Revision Date: 27.08.2021  |  SDS Number: 76217-00021  |  Date of last issue: 08.12.2020  |  Date of first issue: 17.03.2015

ACGIH / TWA : 8-hour, time-weighted average
NZ OEL / WES-TWA : Workplace Exposure Standard - Time Weighted average

AllC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

NZ / EN